Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[New therapies in multiple sclerosis].
Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients.
Cognitive dysfunction in multiple sclerosis.
Practical medical applications of quantitative MR relaxometry.
Dimethyl fumarate - only an anti-psoriatic medication?
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.
Multiple sclerosis and oral health--an update.
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Interventions to evaluate fitness to drive among people with chronic conditions: Systematic review of literature.
[Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate].
Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models.
Therapeutic Armamentarium and Health System Coverage of Multiple Sclerosis in Latin America.
Neuroscience. Myelin--more than insulation.
Pediatric Multiple Sclerosis.
Comprehension and Data-Sharing Behavior of Direct-To-Consumer Genetic Test Customers.
Lipopolysaccharide Upregulates the Expression of CINC-3 and LIX in Primary NG2 Cells.
Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.
siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line.
Anatomical Brain Networks on the Prediction of Abnormal Brain States.
Multiple Sclerosis Disease Progression and Paradichlorobenzene: A Tale of Mothballs and Toilet Cleaner.
Increased resistin levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica.
Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis.
Mice devoid of tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
189
190
191
192
193
194
195
196
197
…
next ›
last »